Mithra – Publication of a transparency notification received from François Fornieri

Liege, Belgium – Mithras (Euronext Brussels: MITRA), a company dedicated to women’s health announces, in accordance with article 14 of the Belgian law of May 2, 2007 concerning the publication of major holdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it has received a transparency notification from Mr. Francois Fornierito February 26, 2022.

Mr Fornieri has notified Mithra that it has exceeded the legal threshold of 25% on February 24, 2022following the repayment of the temporary share loan linked to the exercise of a put option with LDA Capital Limited to December 20, 2021 1. Mr Fornieri now owns 25.18% (11,205,425 shares) of the 44,493,450 shares currently outstanding. Previously, Mr Fornieri held 24.94% of the 44,051,259 shares outstanding.

Detailed transparency notifications are available on the Mithra Investors website (investors.mithra.com). An updated overview of Mithra’s shareholding structure will be included in Mithra’s corporate governance charter, which will be available on its website.

Contact:

Benoit Mathieu

OIR

Phone. : +32 473 35 80 18

Email: investorrelations@mithra.com

About Mithras

Mithras (Euronext: MITRA) is a Belgian biotechnology company dedicated to the transformation women’s health offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products with improved efficacy, safety and convenience, meeting the needs of women throughout their lives. Mithra explores the potential of the unique native estrogen, estetrol, in a wide range of applications in women’s health and beyond. After successfully launching the first estetrol product in 2021, the birth control pill Is she , Mithra is now focusing on its second product Donesta, the next generation hormone therapy. Mithra also develops and manufactures complex therapies in the fields of contraception, menopause and hormone-dependent cancers. It offers its partners a full range of research, development and specialized manufacturing on its Mithra CDMO technology platform. Active in more than 100 countries around the world, Mithra employs around 300 people and is headquartered in Liege, Belgium. www.mithra.com

Important Information

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”. , ‘will’, ‘plans’, ‘continue’, ‘ongoing’, ‘potential’, ‘predict’, ‘project’, ‘target’, ‘seek’ or ‘should’, and include statements made by the Company regarding the expected results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that these forward-looking statements are not guarantees of future performance. The Company’s actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.